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Abstract
The function of the autonomic nervous system is based on reciprocal interaction between the sympathetic and parasympathetic 
parts, most frequently in the form of antagonistic action on target organs. The main mediators of the sympathetic nervous 
system in the effectors part are catecholamines (CA), which are involved in various physiological processes. Moreover, CA 
also has a profound effect on the kidneys, being factors that impact on renal haemodynamics, and have been reported to 
be altered in pathological disorders, e.g. extracellular volume expression, hypertension and cardiovascular complications. 
The increased sympathetic nerve activity, at least in part, can explain the raised in plasma CA observed in chronic kidney 
diseases. Furthermore, plasma CA levels in ureamic patients cannot be considered a reliable index of sympathetic activity, 
due to existence of many factors which may affect their values. In addition, CA released into the circulation, as one of many 
substances, may penetrate across the cellular membranes of erytrocytes (RBC). Taking these observations together, the aim 
of the presented study was to investigate for the first time the plasma and erythrocyte relationship of catecholamines in 
haemodialysis. The studies were performed among 37 haemodialysed patients who were inhabitants of the Lublin commune. 
Plasma and intracellular concentration of CA were measured prior to and following haemodialysis by high performance 
liquid chromatography with electrochemical detection. The results suggest that RBC are able to accumulate CA at the stage 
of terminal renal failure; in addition, the levels of adrenaline and dopamine in RBC depend on the accumulation of urea in 
plasma. It was also found that the dynamic changes in concentration of RBC adrenaline are an independent predictor of 
mortality in haemodialysis patients.
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INTRODUCTION
Chronic kidney disease (CKD) is a syndrome developing 
as a result of congenital or acquired diseases of the urinary 
tract, which is a consequence of end-stage renal failure. 
Nowadays, CKD is a critical and rapidly growing global 
health problem. The prevalence of chronic kidney disease 
is about 10–16%, mainly in the elderly [1, 2]. Clinical 
manifestations of CKD may include a variety of metabolic 
dysfunctions, such as accumulation of uraemic toxic 
substances leading to neurological disorders, in particular, 
sympathetic dysfunction.
The function of the autonomic nervous system is based 
on reciprocal interaction between the sympathetic and 
parasympathetic parts, most frequently in the form of 
antagonistic action on target organs. The main mediators 
of the sympathetic nervous system in the effectors part 
are catecholamines (CA): noradrenaline (NA), adrenaline 
(A) and dopamine (DA). Neurotransmitters are biogenic 
amines derived from the amino acid tyrosine and possess a 
catechol group with an attached amino group [3, 4]. Ther are 
synthesized both in the brain and in the peripheral organs 
and cells, such as the adrenal medulla, non-neuronal gut 
cells, platelets and lymphocytes [4].
These molecules involved in various physiological process, 
inter alia, respond to stress. Moreover, CA also has profound 
effects on the kidney [5], being factors that impact on renal 
haemodynamic, and have been reported to be altered in 
pathological disorders, e.g. extracellular volume expression, 
hypertension and cardiovascular complications [6].
The increased sympathetic nerve activity, at least in part, 
can explain the increased in plasma catecholamines observed 
in CKD. It is also known that catecholamines clearance is 
decreased in CKD. For example, NA clearance is reduced 
by 20% in mild renal failure and by up to 40% in patients 
on haemodialysis (HD) [7, 8]. Catecholamines released into 
the circulation, as one of many substances, may penetrate 
across the cellular membranes as passive diffusion, active 
transport, sodium and potassium pump or anion changing 
system [3, 9, 10, 11]. In the literature [9, 12, 13], there have 
been some reports about the role and transport of circulating 
catecholamines in human red blood cells (RBC). Many 
authors [9, 12, 14, 15] in their series of experiments have 
confirmed that human erythrocytes could transport CA 
from their sites of release to their sites of elimination, or 
are subsequently inactivated by the red cells. Moreover, red 
blood cells may contribute to extraneuronal metabolism 
of CA by the processes of methylation or sulfoconjugation, 
although the nature and magnitude of this phenomenon still 
remains unclear. Especially little is known about the role 
and transport of circulating CA in RBC patients who have 
CKD. Furthermore, plasma CA levels in uraemic patients 
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cannot be considered a reliable index of sympathetic activity; 
studies using microneurographic techniques confirmed that 
sympathetic overactivity is often present in uraemia [16].
Therefore, the aim of the presented study was to investigate 
the plasma and erythrocyte relationship of catecholamines 
in haemodialysis.
MATERIALS AND METHOD
The studies were performed among 37 hemodialysed patients 
who were inhabitants of the commune Lublin – 17 women 
and 20 men, aged 26–85 years, with the median duration 
of haemodialysis of 3.5 years. The control group comprised 
22 healthy subjects matched for age to the study group, 
undergoing prophylactic examinations at the Department of 
Laboratory Diagnostics at the Medical University in Lublin, 
south-east Poland. Standard phlebotomy techniques were 
used to obtain samples. The study protocol was approved 
by the local Ethics Committee at the Medical University in 
Lublin. Written informed consent was obtained from each 
patient qualified to participate in the study. All patients 
underwent a clinical examination at the Department of 
Nephrology of the Medical University in Lublin. Samples 
of venous blood were collected to dry tubes without 
anticoagulant, and centrifuged immediately. The samples 
were either used for measurements immediately or stored 
frozen at -80 °C. In the serum, concentration of creatinine, 
total protein, albumin and urea were measured prior to and 
following haemodialysis using routine laboratory methods. 
Similarly, haematology testing was performed with blood.
Sampling. Analysis of levels of catecholamines in biological 
fluids has necessitated the use of highly sensitive analytical 
techniques.
Extraction of catecholamines from erythrocytes. Blood was 
collected into K3EDTA (7.5 ml) via intravenous catheter, after 
the patients had rested for 20 min in the supine position. To 
isolate erythrocytes, the blood samples were subjected to low 
speed centrifugation (225 × g, 15 min) at +4 °C, and aspirated 
to the supernatant platelet rich plasma. The samples were then 
centrifuge at high speed (10,000 × g, 10 min) and aspirate the 
platelets poor plasma and buffy coat layers. The erythrocytes 
were then washed with an equal volume of physiological 
saline and centrifuged (10,000  ×  g, 10 min) three times at 
+4  °C. After that, 1 ml of densely-packed erythrocytes 
were added to 1 ml of ice-cold deionized water. The lysis 
of erythrocytes were resuspended in equal volumes (2 ml) 
into the tubes containing 120 µl of a preservative solution 
(900 mg of EGTA and 700 mg of reduction glutathione in 8 ml 
of 0.5 N NaOH). After vigorous agitation, the samples were 
stored at -80 °C until assayed. Extractions of catecholamines 
from plasma and erythrocytes lysate was carried out with a 
ChromSystems Reagent kit for HPLC analysis. Plasma and 
intracellular concentration of catecholamines were measured 
prior to and following haemodialysis by the method of high 
performance liquid chromatography with electrochemical 
detection (HPLC-ED).
Statistical analysis. All values are expressed as mean and 
standard deviations. Distributions of the analyzed variables 
were tested using the Shapiro-Wilk test. For a comparison 
of the obtained results of investigations in the case of 
normally distributed variables, the Student t-test was used. 
For variables that did not demonstrated compliance with 
the normal distribution, the non-parametric U Mann-
Whitney test was used. Correlations between variables 
were investigated using Spearman`s test. In all tests, p-value 
<0.05 was considered significant. All statistical analyses were 
conducted using the Statistica 10.0 software. In order to 
investigate the diagnostic value of erythrocytes and plasma 
catecholamines were plotted by the ROC (Receiver Operating 
Characteristic) curve, and the area under the curve (AUC) 
was calculated to describe the capability of the markers to 
discriminate between dead and live haemodialysis patients 
during two years observation. For this, MedCalc ver. 11.4.3.0 
software was used.
RESULTS
Baseline characteristics of the study population are shown 
in Table 1 and selected laboratory parameters in Table 2. In 
the examined group of haemodialysis patients, significant 
differences were found concerning creatinine, blood urea 
nitrogen (BUN), total protein (TP), albumin, hematocrit 
(HCT),haemoglobin (HGB), red blood cells (RBC), mean 
corpuscular haemoglobin concentration (MCHC) mean 
cell corpuscular volume (MCV), in comparision with the 
control group. Plasma and erythrocyte catecholamines of 
the analysed population are shown in Table 3. As a result of 
the conducted studies, it was found that the plasma levels of 
noradrenaline (550.36 pg/ml) was significantly elevated in 
comparison with the control group (234.93 pg/ml p<0.001), 
Table 1. Baseline characteristics of the study population
Parameter
HD patients
N = 37
Reference group
N = 22
Age (years)   67.02 ± 12.89   58.2 ± 13.1
BMI (kg/m2)   26.4 ± 4.57   21.5 ± 4.1
Systolic blond pressure (mmHg) 124.64 ± 12.49 121.8 ± 12.3
Diastolic blood pressure (mmHg)   74.41 ± 11.59   73.6 ± 6.7
Pulse pressure (mmHg)   50.23 ± 13.28   50.1 ± 10.2
Table 2. Selected biochemical and haematological parameters of HD 
patients and reference group
Parameter
HD patients
N = 37
Reference group
N = 22
Creatinine (mg/dl)   9.1 ± 1.8***   0.8 ± 0.2
BUN (mmol/l) 19.95 ± 4.72***   4.23 ± 1.24
TP (g/dl)   6.75 ± 0.75**   7.2 ± 0.3
Albumin (g/dl)   3.76 ± 0.43**   4.3 ± 0.4
HCT (%) 31.91 ± 3.34*** 41.28 ± 2.82
HGB (g/dl) 10.50 ± 1.21*** 14.09 ± 0.7
RBC (1012/l)   3.47 ± 0.39***   4.58 ± 0.032
MCV (fl) 90.42 ± 10.62 90.15 ± 2.65
MCH (pg) 30.26 ± 2.15 30.8 ± 1.33
MCHC (g/dl) 32.88 ± 1.56*** 34.18 ± 1.13
Dialysis period (h)   4.6 ± 0.2
*** p<0.001 **p<0.01 * p<0.05 – HD patients vs. reference group
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whereas plasma concentration of adrenaline (56.49 pg/ml; 
p>0.05) and dopamine (39.04 pg/ml, p>0.05) were not elevated. 
Furthermore, no significant differences were found between 
the level of NA in erythrocytes (p>0.05) in both study 
population, as opposed to values of A (p<0.001) and DA 
in RBC (p<0.001) (Tab. 3). The results presented in Table 3 
indicate statistically significant differences between CA in 
RBC and plasma (p<0.001). In other words, the concentration 
of A, DA in RBC were higher than those found in plasma. 
Accumulation of circulating catecholamines in erythrocytes 
was compared to rising plasma levels of catecholamines. 
Accumulation of CA in RBC was estimated by the ratio 
of their erythrocytes/plasma (E/P) concentration. The 
ratio of NA (0.25; p<0.001) and DA (2.75; p<0.01) in the 
group of haemodialysis patients were significantly lower 
than those observed in the control group (NA 1.7; DA 7.8) 
(Tab. 3). After taking into consideration the patients gender, 
no significant differences were found in the plasma and 
erythrocytes CA depending on the patients gender. CA 
concentration before and after HD treatment are presented 
in Table 4. The results indicated that NA (550.36 pg/ml) 
in plasma had a significantly lower concentration after 
haemodialysis treatment (417.98 pg/ml p<0.001). However, 
values for NA (153.21 pg/ml) and A (263.36 pg/ml) in RBC 
before haemodialysis were higher than after haemodialysis 
(NA 144.32 pg/ml A 253.14 pg/ml), whereas an inverse 
relationship was noted for DA before HD (126.05 pg/ml) 
and after HD (142.07 pg/ml). The observed differences were 
slight and not statistically significant. Univariate correlations 
of circulating CA concentrations are presented in Table 5. 
According to the correlations analysis, the plasma levels of 
A were directly proportional to the concentration of urea 
before and after haemodialysis (rs= 0.33 p<0.05 and rs= 0.34 
p<0.05). Therefore, it was confirmed that there was a negative 
correlation between the values of A, DA in RBC and levels of 
urea before and after haemodialysis (Tab. 5). A statistically 
significant negative correlation was found to exist between 
the E/P ratio of A (before and after HD) and urea values 
(rs= -0.38 p<0.01;rs= -0.37 p<0.01). Changes in the value of 
catecholamines induced by haemodialysis treatment are 
presented as the delta values (Δ) among the dead and living 
patients (Tab. 6). This ratio was calculated based on the 
difference in concentrations of catecholamines determined 
before and after haemodialysis treatment. Significant 
differences were observed between Δ NA RBC (p<0.01) and 
Δ A RBC (p<0.01) among dead and living patients during two 
years of observation. In contrast, no significant differences 
were observed in the other values of E/P. Figure 1 shows the 
ROC curve for the delta RBC adrenaline values. Diagnostic 
sensitivity and specificity of delta A RBC positive and negative 
Table 6. Changes in value of catecholamines induced by haemodialysis 
treatment among dead and living patients during two-year observation
CA
Dead
N = 28
x ± SD
Me
Living
N = 9
x ± SD
Me
P
Plasma
Δ NA
–249.19 ± 345.7
–257.34
–92.58 ± 411.4
–226.09
> 0.05
Δ A
–31.85 ± 124.39
–10.9
7.14 ± 30.66
10.51
> 0.05
Δ DA
2.12 ± 22.54
2.64
–1.77 ± 31.33
–4.74
> 0.05
RBC
Δ NA
–142.94 ± 475.54
–31.58
24.8 ± 165.4
–2.09
< 0.01
Δ A
–91.41 ± 564.57
–21.225
165.39 ± 438.19
75.56
< 0.01
Δ DA
15.97 ± 194.92
–10.37
–42.57 ± 243.27
–13.57
> 0.05
Table 3. Plasma and erythrocyte catecholamines of the analyse 
population
HD patients
N = 37
Reference group
N = 22
P
NA [pg/ml]
Me
Plasma 550.36 234.93 <0.001
RBC 153.21*** 234.89*** >0.05
E/P   0.25 1.07 <0.001
A [pg/ml]
Me
Plasma  56.49 45.01 >0.05
RBC 263.36*** 132.18*** <0.001
E/P   3.92 2.88 >0.05
DA [pg/ml]
Me
Plasma  39.04 39.94 >0.05
RBC 126.05*** 294.1*** <0.001
E/P   2.75 7.8 <0.01
*** p<0.001 **p<0.01 * p<0.05 – RBC vs. Plasma
Table 4. Catecholamines concentration before and after HD treatment
Before HD
N = 37
After HD
N = 37
P
NA [pg/ml]
Me
Plasma 550.36 417.98 <0.001
RBC 153.21 144.32 >0.05
E/P   0.25   0.35 >0.05
A [pg/ml]
Me
Plasma  56.49  40.70 >0.05
RBC 263.36 253.14 >0.05
E/P   3.92   4.88 >0.05
DA [pg/ml]
Me
Plasma  39.04  43.64 >0.05
RBC 126.05 142.07 >0.05
E/P   2.75   2.72 >0.05
Table 5. Univariate correlations of serum urea in the study population
Correlates rs P*
Before HD RBC A [pg/ml] vs. After HD Urea [mmol/l] –0.39 < 0.01
Before HD RBC A [pg/ml] vs. After HD Urea [mmol/l] –0.40 < 0.01
Before HD RBC DA [pg/ml] vs. After HD Urea [mmol/l] –0.36 < 0.01
Before HD Plasma A [pg/ml] vs. After HD Urea [mmol/l] 0.33 < 0.01
Before HD Plasma A [pg/ml] vs. After HD Urea [mmol/l] 0.34 < 0.01
Before HD R/P A vs. Before HD Urea [mmol/l] –0.38 < 0.01
Before HD R/P A vs. Before HD Urea [mmol/l] –0.37 < 0.01
*Significant correlations assessed by Spearman correlation method
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predictive values for cut-off value 44.87 pg/ml were 77.8% 
and 82.1%, respectively. The area under the curve equal to 
0.74 (p<0.01) indicates a good diagnostic usefulness of RBC 
adrenaline as an independent predictor of mortality.
DISCUSSION
The majority of reports [17, 18] on CA in haemodialysis 
patients describe disturbances of the plasma levels of 
CA. The presented study confirms the results of previous 
studies in which plasma catecholamines are increased in 
HD patients. It has to be pointed out that an increased level 
of CA in plasma is common and due to impaired central 
dopaminergic control. Recently, research on metabolizes 
circulating CA have focused on renalase. This is a new, flavin-
adenin dinucleotide (FAD) containing hormone secreted 
by the kidneys and circulates in the blood, and may play a 
key role in metabolizing CA [19,20,21]. As blood levels are 
markedly reduced in end-stage renal disease, this suggests a 
higher concentration of plasma catecholamines [22]. Renalase 
deficiency may contribute to the heightened sympathetic 
tone observed in CKD. What is interestingly is that various 
stressors are able to stimulate levels and production of CA in 
adipocytes [23]. However, there is still a lack of information 
concerning the full characterization of adipocytes and CA 
production.
As mentioned earlier, plasma CA levels in uraemic patients 
cannot be considered a reliable index of sympathetic activity 
[16]. Thus, in the presented study, level of CA in RBC were 
determined for the first time in haemodialysis patients. 
Likewise, the accumulation of catecholamines in erythrocytes 
was compared to plasma levels of catecholamines. This 
demonstrated that in haemodialysis patients the levels of 
A and DA in RBC were significantly elevated compared to 
plasma concentration, while NA values in RBC were lower 
than in plasma. This suggests that RBC are able to uptake 
plasma CA. In addition, this is confirms by the ratio of 
their erythrocytes/plasma concentration (E/P), with no 
assumption as to whether CA cross the RBC membrane 
or remain absorbed at their surface. Thus, the response of 
human RBC to increased concentrations of CA in plasma 
is dependent on the amine structure and on the plasma 
concentration. However, the data presented here are consistent 
with a study by Alexander [24] which found that under 
physiological conditions, DA, NA and A concentrations 
in blood cells are higher than those in plasma. This fact 
might reflect homeostasis due to the adaptive mechanism 
of the accumulation of CA in RBC. As a matter of fact, the 
increased ability of erythrocytes to accumulate dopamine 
and adrenaline confirms the existence of active transport [9].
Analysis of the results obtained in the control group 
indicated a slight difference between RBC and plasma 
concentration of NA (RBC NA 234.89 pg/ml; plasma NA 
234.93 pg/ml). This suggests that passive transport is involved 
in the transmission of NA through the cell membrane. Taken 
together, the accumulation CA in RBC markedly reduced 
the level of renalase in plasma patients with end-stage renal 
disease [25], and the presence of processes of methylation or 
sulfoconjugation in RBC [26], it seems that RBC might play 
a role in metabolizing CA. In the haemodialysis patients 
in the presented study, a significant relationship was noted 
between concentrations of A and DA in RBC and the level of 
urea in plasma (Tab. 5). These studies support the notion that 
levels of DA and A in RBC might be part of the mechanism 
of uraemic toxins. Urea is the main uraemic toxin and the 
nitrogenous end-product of protein metabolism; it is also 
the most abundant nitrogenous product that accumulates in 
CKD. Thus, it is possible that urea could cause a significant 
reduction in CA transport from plasma to RBC during HD. 
As confirmed by the results, in haemodialysis patients the 
level of CA in RBC are decreased, compared with the values of 
CA in RBC of the control group. It is interesting to note that in 
the research by Bonomini and Sirolli [27], the uremic toxins 
were significantly influenced by the viability of RBC. Thus, 
uraemic toxins induce and modify the quantity and quality 
composition of phospholipids of red blood cells membrane. 
On the other hand, the oxidative stress accompanying 
chronic renal failure and haemodialysis processes may cause 
a number of interferences [28, 29, 30, 31]. Disturbances of 
the chemical composition of the erythrocyte membrane, 
anomaly of the haemoglobin structure, disturbances of 
glycolytion and oxidation reduction enzymes, in general 
leads to a shorter RBC lifespan and contributes to renal 
anaemia.
Raised sympathetic activity is now recognized as 
an important mechanism involved in cardiovascular 
complication in humans. During two years observation, nine 
deaths were observed through a cardiac event. In agreement 
with data from the medical literature, that in the course of 
chronic kidney insufficiency due to renal impairment, nearly 
50% of deaths among patients with end-stage renal disease 
were due to cardiovascular diseases [32]. The risk of death is 
higher in the haemodialysed than the general population [1]. 
In the presented study, diagnostic sensitivity and specificity 
of Δ A RBC for the cut-off value 44.87 pg/ml were calculated 
on the basis of this result, and it can be supposed that the 
dynamic change in the concentration of adrenaline in RBC 
of HD is an independent predictor of mortality. It may 
also be speculated that the CA release from RBC would 
participate in the regulation of the immune processes 
and inflammatory responses contributing myocardial 
remodeling. This hypothesis is similar to that in which T cells 
also can release catecholamines, and are an integral part and 
potent modulators of these neuro-endocrine-immune and 
inflammatory interactive networks [4, 33, 34]. Nonetheless, 
the presented data should be cautiously interpreted because 
Figure 1. Receiver-operating characteristics curie for Δ A RBC in haemodialysis 
patients
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the development of cardiovascular complications are complex 
processes. We are at the beginning of solving the problem of 
whether dynamic change in the concentration of adrenaline is 
a causative factor of mortality, or just an ‘innocent bystander’. 
On the other hand, it is known for sure that the role of 
plasma CA, especially NA as an indicator of cardiovascular 
events in HD patients, was previously well established [35]. In 
Mallamaci`s study, interactions between NA and Asymmetric 
Dimethyl Arginine (ADMA) levels among patients with end-
stage renal disease, remains an independent risk factor for 
predicting adverse cardiovascular outcomes, and are strongly 
associated with left ventricular concentric hypertrophy and 
left ventricular systolic dysfunction [35]. Prospective studies 
are needed to better elucidate the role of RBC in the metabolic 
CA of haemodialysis patients.
CONCLUSIONS
The presented results suggest that RBC are able to accumulate 
CA at the stage of terminal renal failure; in addition, the 
levels of A, DA in RBC depend on the accumulation of 
urea in plasma. It was also found that the dynamic changes 
in concentration of RBC adrenaline are an independent 
predictor of mortality in haemodialysis patients.
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